Page 6 - Pharmaceutical Firms

Trump says tariffs on chips and pharma imports to be announced soon

President Trump has said tariffs on pharmaceutical and semiconductor imports will be announced shortly, as the US imposes a 27% duty on all imports from India

India's pharma industry gets relief from Trump's reciprocal tariff

US President says India imposes 52% tariff on American imports and engages in currency manipulation and non-tariff barriers

Trump's pharma tariffs threaten global supply chains, patient access

Protectionist policies will raise the prices of active ingredients for these producers, many of whom may have little recourse to return manufacturing to the US in the short term

Will US tariffs succeed in lifting the veil on India's drug safety problem?

Over 30 per cent of Indian pharma exports go to the US, and it provides an even larger proportion of earnings

Zydus Life extends timeline for Sterling Biotech API business acquisition

The company had first disclosed the deal on September 17, 2024, after signing a business transfer agreement (BTA) with SBL

Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..

Marksans Pharma up 3% as arm secures marketing authorisation for Baclofen

The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received Marketing Authorisation for the product Baclofen 10 mg Tablets from UK MHRA

Generics surge as patent expiry restores mkt pulse, boosting drug volumes

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in the market after Novartis' patent expired in December 2019

Drugmakers Mallinckrodt, Endo agree to merge in nearly $7 billion deal

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion

IPA refutes US univ's report questioning quality of Indian-made generics

Industry insiders pointed out that since India accounts for nearly 50 per cent of the generic drugs exported to the US, the share of adverse events also would be higher on a proportionate basis

Despite near-term challenges, brokerages remain positive on Sun Pharma

The recent trigger for the stock is the acquisition of US-based Checkpoint Therapeutics

Funds under PRIP scheme likely to be sanctioned by August 2025: DoP

The department had last week sought expressions of interest from interested entities for project funding under the PRIP scheme

Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn

Sun Pharma plans to leverage its global presence to accelerate patient access to this crucial treatment

Aveo Pharma suspects misuse of painkiller Tafrodol in importing countries

The company also clarified that the "stop production" order of Feb 24 was due to compliance issues under the Schedule M of the Drugs and Cosmetics Rules, 1945, and not due to the combination product

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

CDSCO plans to streamline drug export clearances to reduce workload

The agency has only 2,000 officials to oversee over 10,000 drug factories and 1 million pharmacies in India

Venus Remedies to co-develop antibiotic resistance blocker with UK firm

Clinical trials to start next year, and drug can be in market by 2031-32